MEDICAMEN BIOTECH LTD (BSE Code: 531146) BB: MDCB IN

MEDICAMEN BIOTECH LTD (BSE Code: 531146) BB: MDCB IN BUY @ CMP: 84.40 Date: 25th April, 2016
ENDEAVOUR

Established in Dec.’ 1993, Medicamen today represents a family with a long tradition in the development and manufacture of quality pharmaceuticals for the service of ailing masses through medical fraternity to accomplish minimisation of human misery.
This commitment to quality healthcare is guided by a clear vision and an eagerness to accept competition & challenges down the line.

EXCELLENCE

Right from the outset, excellence with professional integrity has been the keynote of Medicamen’s work culture. Excellence is thus reflected in its product quality, services & operations.

DOMAIN OF OPERATION

Medicamen has two finished formulation Plants-One at Bhiwadi (Rajasthan) and other at Haridwar (U.K.) The Bhiwadi plant is constructed in an area of 210,000 sq. ft. The constructed area is conceptualized on the block system comprising five block; each block has a covered area of about 20,000 sq. ft. The different blocks house different sections of manufacture viz. Beta-lactum (Penicillin) block, Non-Beta-lactum (Non-Pencillion Block, Cephlosporin Block, ORS and Oral liquid block, R & D quality control departments, store and the utility block. At Haridwar the company is having a single three storied manufacturing unit to manufacture Non-Betalectum range of product including Iron-Folic Acid tablets, ointments and lotions.

The installed manufacturing capacity per day of the plant is depicted graphically as under:


MEMBERSHIPS & REGISTRATION

Medicamen is an active member of Confederation of Indian Industries (CII),Federation of Indian Chambers of Commerce & Industry (FICCI), Indian Drug Manufacturers’ Association (IDMA) & Federation of Indian Export Organisation (FIEO). The company is also registered with FDA, Rajasthan and FDA, Uttrakhand (INDIA)| for a wide range of pharmaceutical formulations & is a member of PHARMEXIL. The management is actively represented on the various committees of FICCI, IDMA & PHARMEXIL.

TEAM OF PROFESSIONALS

Medicamen’s driving force is its highly skilled human resource base. Its team comprises 48 qualified industrial pharmacists, 19 quality assurance pharmacist & more than 100 technicians and workers working in a very conducive environment.


VISION

To emerge as a preferred pharmaceutical company in India with leadership in quality, market share and Profit by Inculcating a high performance culture. Following the highest standard of honest workmanship in whatever we do. Ensuring that the method we use is in line with the latest technology world over. Walking the extra mile to satisfactorily serve the healthcare needs at most competitive considerations, being the partner of choice for our associates both overseas & domestic. Ultimately, to uplift our obligations as the trustee of our customers, employees, shareholders and society.

MEDICAMEN BIOTECH LIMITED is a widely accepted Company in International Market specially in African, Latin/Central American, Phar-East and CIS countries. The Company has been accredited with registrations in Pan American Health Organization,CHAI formerly Clinton Foundation, ANVISA of Brazil etc.  The Company has embarked upon a massive programme of exporting its products to several countries from which there is enormous demand and enquiries for its formulations.  Over the next few years there is expectation of a huge spurt in revenue from export business.

Medicamen Biotech Ltd. has finalised tie ups with highly reputed pharmaceutical importers and distributors in Africa, Central America/South America, Brazil, CIS and South east Asia to market its products.  The company has a well equipped Regulatory affairs Department to provide the registration requirements for the Ministries of Health, FDA and Regulatory authorities of various countries.  It has a strong data bank for DMFs, BE Studies and CTD/ACTD dossiers.

Medicamen Biotech Ltd. is having an annual growth rate of around 15% and is planning to export goods worth at least 20 million over the next three years.  The Company is planning to intensify its activities in the product segment of Anti-diahreal, Anti-malarial, Anti-TB, Antibiotics, Anti-diabetic, Cardiovascular drugs.  Besides, the Company will keep exploring new molecules and formulations so as to meet the ever increasing demand of Medical Fraternity.  The Company is planning for pre-qualification of one of its product with WHO-GENEVA and the work is going in full swing.  The Company has long-term plan to enter the Regulated Markets like UKMHR and TGA.